LivaNova (LivaNova) Interest Expense : $-59 Mil (TTM As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is LivaNova Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. LivaNova's interest expense for the three months ended in Dec. 2023 was $ -16 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-59 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. LivaNova's Operating Income for the three months ended in Dec. 2023 was $ 2 Mil. LivaNova's Interest Expense for the three months ended in Dec. 2023 was $ -16 Mil. LivaNova's Interest Coverage for the quarter that ended in Dec. 2023 was 0.13. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

LivaNova Interest Expense Historical Data

The historical data trend for LivaNova's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova Interest Expense Chart

LivaNova Annual Data

Trend

Apr14

Apr15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-15.09

-40.84

-50.15

-48.25

-58.85

LivaNova Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-13.36	-13.44	-14.81	-14.99	-15.62

LivaNova Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59 Mil.

LivaNova (NAS:LIVN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

LivaNova's Interest Expense for the three months ended in Dec. 2023 was $-16 Mil. Its Operating Income for the three months ended in Dec. 2023 was $2 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $614 Mil.

LivaNova's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	1.984	/	-15.621
	=	0.13

The higher the ratio, the stronger the company's financial strength is.

LivaNova (LivaNova) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

LIA:Germany

Address

20 Eastbourne Terrace, London, GBR, W2 6LG

Website

https://www.livanova.com

U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.

Executives

James Christopher Barry	director	7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald	officer: COO	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson	officer: Chief Legal Officer	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story	director	C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver	director
Daniel Jeffrey Moore	director	100 CYBERONICS BVLD, HOUSTON TX 77058
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy	director	C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci	officer: SVP Global Operations, R&D	VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn	director	C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg	officer: Interim CFO	20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury	officer: President, International	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston	officer: Chief Financial Officer	941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing	director	C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601
Trui Hebbelinck	officer: Chief Human Resources Officer	20 EASTBOURNE TERRACE, LONDON X0 W2 6LG